Although the QR result is within expectation. The current price has more or less been priced in. Hence the upside for glove for next few quarters will not be so attractive. Expect more profit taking after this and people will slowly collect the next theme which is vaccine.
Remdesivir, the only antiviral drug authorized to treat COVID-19 could become far more accessible soon. On Monday, Gilead Sciences (NASDAQ:GILD) finished submitting a new drug application (NDA) to the FDA that could lead to full approval of the broad-spectrum antiviral, to be marketed as a treatment for COVID-19 under the brand name Veklury
Q1 8.57 x4 = 34.25 x 10.5 = 3.6 support but resistance at 5.5 or 16.04 PE So if Q2 at 12 sen x 4 at would 5.04 n 7.70 meaning Dtop to complete 7.5 cup from 2015
Better put it at 10sen eps per q going forward.Price 4.6-4.8will give the PE ~12x which is undemanding thus undervalued!Coupled with small share volume and float this is a near perfect candidate for speculative play and thus TP rm8-10 in next few months buoyed by covid vaccine news!
it is normal the q2 results not as good as q1, due to mco, it is expected, no need to highlight again and again, haha. With all that vaccine progress, i think vaccine will be ready, soon than we anticipated.
vaccine news impact not so good actually, to overall bursa index, as people will start collect profit from glove counters, pushing down index, all counter affected, more sell pressure, chain of panic sell continue. but at least, other sector price will start to stabilise too, as people will not focus to health care only.
Indonesia starts human trials of China-made virus vaccine Updated 20 minutes ago · Published on 11 Aug 2020 7:00PM · 0 Comments More A
Indonesia will start human trials of a China-made Covid-19 vaccine, with 1,600 volunteers participating in the six-month study. – EPA pic, August 11, 2020.
INDONESIA today launched human trials of a Chinese-made coronavirus vaccine with some 1,600 volunteers slated to take part in the six-month study.
The vaccine candidate, produced by Sinovac Biotech, is among just a few in the world to enter Phase 3 clinical trials, or large-scale testing on humans – the last step before regulatory approval.
1. Dpharma - Packaging and bottling of Covid-19 vaccines
2. Pharma - Packaging and bottling of Covid-19 vaccines
3. Titijaya - Tie up with China's Sinopharm (State owned vaccine producer for China that is currently performing Phase III trials in Saudi Arabia. Could be doing vaccine hub via property development
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
Report Abuse
Please Sign In to report this post as abuse.
Market Buzz
No result.
Featured Posts
MQ Trader
Introducing MY's First IPO Fund for Sophisticated Investors!
MQ Chat
New Update. Discover investment communities that resonate with your ideas
MQ Trader
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
0:17
New IPO: The largest mini-market player and a leading groceries retailer in Malaysia, 99 Speed Mart Retail Holdings Bhd aims to list on the Main Market!
MQ Trader 695 views | 3 d ago
0:17
New IPO: An enterprise IT solutions provider that provides implementation services, maintenance, support and professional services, Vetece Holdings Bhd aims to list on the Ace Market!
MQ Trader 670 views | 7 d ago
0:17
New IPO: A manufacturing and trading of biomass fuel products, particularly PKS and wood pellets company, Elridge Energy Holdings Bhd aims to list on the Ace Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
XiuyyXiong
134 posts
Posted by XiuyyXiong > 2020-08-10 17:11 | Report Abuse
q1029384756, true ?
could u give me the news link